Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
anti-TRAIL-R3 (human), mAb (HS301)
460
CHF
CHF 460.00
In stock
AG-20B-0024-C100100 µgCHF 460.00
| Product Details | |
|---|---|
| Synonyms | TRAIL Receptor 3; DcR1; TRID; TNFRSF10C; CD263 |
| Product Type | Monoclonal Antibody |
| Properties | |
| Clone | HS301 |
| Isotype | Mouse IgG1 |
| Source/Host | Purified from concentrated hybridoma tissue culture supernatant. |
| Immunogen/Antigen | Recombinant human TRAIL-R3 (DcR1). |
| Application |
Flow Cytometry |
| Crossreactivity | Human |
| Specificity |
Recognizes human TRAIL-R3. Does not cross-react with human TRAIL-R1, -R2 or -R4. |
| Purity | ≥95% (SDS-PAGE) |
| Purity Detail | Protein G-affinity purified. |
| Concentration | 1mg/ml |
| Formulation | Liquid. In PBS containing 10% glycerol and 0.02% sodium azide. |
| Isotype Negative Control | |
| Shipping and Handling | |
| Shipping | BLUE ICE |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
After opening, prepare aliquots and store at -20°C. Avoid freeze/thaw cycles. |
| Use/Stability | Stable for at least 1 year after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
TRAIL-R3 is a receptor for the cytotoxic ligand TRAIL. It lacks a cytoplasmic death domain and hence is not capable of inducing apoptosis. Protects cells against TRAIL mediated apoptosis by competing with TRAIL-R1 and R2 for binding to the ligand.
Product References
- TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus: B. Washburn, et al.; J. Immunol. 170, 1814 (2003)
- TRAIL regulates normal erythroid maturation through an ERK-dependent pathway: P. Secchiero, et al.; Blood 103, 517 (2004)
- Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al.; Cell Death Differ. 11 Suppl 1, 86 (2004)
- cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes: T. Wachter, et al.; J. Biol. Chem. 279, 52824 (2004)
- Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression: E. Contassot, et al.; Blood 111, 4780 (2008)
- The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2: T. Hartwig, et al.; Mol. Cell 65, 730 (2017)
Related Products
